CD36 inhibition enhances the anti-proliferative effects of PI3K inhibitors in PTEN-loss anti-HER2 resistant breast cancer cells
Abstract Background HER2-positive patients comprise approximately 20% of breast cancer cases, with HER2-targeted therapy significantly improving progression-free and overall survival. However, subsequent reprogramed tumor progression due to PI3K signaling pathway activation by PIK3CA mutations and/o...
Saved in:
| Main Authors: | You-Yu Liu, Wei-Lun Huang, Sin-Tian Wang, Hui-Ping Hsu, Tzu-Ching Kao, Wei-Pang Chung, Kung-Chia Young |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | Cancer & Metabolism |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40170-025-00375-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Identification of new selective CD36 inhibitors to potentiate HER2-targeted therapy in HER2-positive breast cancer
by: Lorenzo Castagnoli, et al.
Published: (2025-08-01) -
CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer
by: Lorenzo Castagnoli, et al.
Published: (2025-01-01) -
Niraparib restricts intraperitoneal metastases of ovarian cancer by eliciting CD36-dependent ferroptosis
by: Ning Jin, et al.
Published: (2025-03-01) -
Effects of different long-chain fatty acids on lipid uptake and CD36 palmitoylation in small intestinal epithelial cells of mouse
by: Lilin CAI, et al.
Published: (2025-09-01) -
The role and mechanism of action of endoplasmic reticulum transmembrane protein 166 in liver lipid metabolism
by: LI Lianhui, YANG Di, ZANG Kailai, SUN Yani, DU Qiyuan, LI Ning
Published: (2025-08-01)